Please note that these webinars were recorded in 20167. All AMPEDTM content is reviewed and approved annually by the Training & Education Committee as relevant and accurate, but new data may now be available and new studies may have since been published.
AMP Education is constantly updating these educational offerings, so keep checking back at educate.amp.org for new content, content updates, and information on cutting-edge molecular pathology research and applications.
Description:
Recent definitions for clinical utility of molecular tests focus on whether a test result will alter treatment. This definition neglects other uses of molecular testing to diagnose disease, manage symptoms, prognosticate or predict future disease. The fullest realization of precision medicine will require embracing all aspects of clinical utility. This three-part webinar series, supported by AMP, presents the discussions of AMP’s Framework for the Evidence Needed to Demonstrate Clinical Utility (FEND) working group, and its resulting publication, “The Spectrum of Clinical Utilities in Molecular Pathology Testing Procedures for Inherited Conditions and Cancer: A Report of the Association for Molecular Pathology” (Joseph L, et al. J Mol Diagn. 2016;18[5]:605–619).
Learning Objectives:
- Discuss the background and future of cancer genomics testing.
- Describe a modified ACCE model for determining clinical utility for genetic tests.
- List types of evidences that demonstrate clinical utility.
- Discuss how different definitions of clinical utility apply to molecular tests.
- Discuss the utility of testing in the absence of an established treatment plan.
- Recognize the breadth of clinical utility in the molecular testing of solid tumors and hematologic malignancies.
- Recognize the limitations of current definitions of clinical utility for inherited conditions.
- Define clinical validity and utility for inherited conditions.
- Identify the efficiencies and economies of molecular oncology testing.
- Identify a more inclusive view of clinical utility for inherited conditions.
This webinar discusses the current landscape of definitions for clinical utility, and then present a modified Analytical Validity, Clinical Validity, Clinical Utility and Associated Ethical, Legal and Social Implications (ACCE) framework. With this model the speakers explore the spectrum of clinical utilities, and evidences needed to demonstrate utility for all stakeholders, with a focus on patient-centered utility.
Host: Roger Klein, MD, JD
The spectrum of clinical utility in solid tumor and hematologic malignancies will be discussed, focusing on diagnostic, prognostic, predictive and therapeutic options. In addition, the importance of diagnosis in the absence of an established treatment plan and the overall efficiency to the health care system will also be addressed.
Host: Loren Joseph, MD
Part 3: AMP’s Framework for the Evidence Needed to Demonstrate Clinical Utility – Inherited Conditions
This webinar will focus on an understanding of clinical utility in molecular pathology testing for inherited disease. We will review the limitations of the clinical utility models as they are currently defined and applied. We will then discuss a more comprehensive and pragmatic view that ensures appropriate access to care for those with inherited conditions.
Host: Elaine Lyon, PhD
Practice Guideline Available Here
Total Duration: 3 hr
Level of Instruction: Intermediate
Recording Date: September 28, 2016Note: Join the AMP Family for discounted access to the most current educational resources!
All sales are final. No refunds will be issued.
No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.
